Dr. Meir Kryger, professor of medicine at Yale School of Medicine and editor of 'Principles and Practice of Sleep Medicine,' estimates that the true prevalence of OSA may be 50% higher than current figures suggest. A 2019 Lancet Respiratory Medicine study (n=936 million adults across 16 countries) found that nearly 1 billion people worldwide have mild-to-severe OSA, with men 2-3 times more likely to be affected than premenopausal women. Obstructive sleep apnea affects an estimated 22 million Americans, yet 80% of moderate-to-severe cases remain undiagnosed. Untreated moderate-to-severe OSA doubles cardiovascular mortality risk.
The classic presentation (overweight male who snores loudly) captures only a fraction of cases. Women are underdiagnosed because they more frequently present with fatigue, insomnia, and morning headaches rather than loud snoring.
Diagnosis has shifted from mandatory in-lab polysomnography to home sleep testing for uncomplicated cases. Level III home devices measure airflow, respiratory effort, and oxygen saturation. Dr. Atul Malhotra, chief of pulmonary, critical care, and sleep medicine at UC San Diego and editor-in-chief of the American Journal of Respiratory and Critical Care Medicine, notes that home testing has reduced the diagnostic gap but cannot detect central sleep apnea or comorbid sleep disorders.
CPAP remains the first-line treatment. The SAVE trial (NEJM 2016, n=2,717) led by Dr. R. Doug McEvoy at Flinders University found that CPAP significantly improved quality of life, daytime sleepiness (Epworth score reduced by 2.5 points), and depression symptoms, though it did not reduce the primary composite cardiovascular endpoint. Efficacy is unquestioned when used consistently, but 30-50% of patients abandon CPAP within the first year.
Alternatives include mandibular advancement devices, which an Oral Surgery meta-analysis (k=14, n=834) found reduce AHI by 50-60% in mild-to-moderate cases. Hypoglossal nerve stimulation — the Inspire device, validated in the STAR trial (n=126) by Dr. Patrick Strollo at the University of Pittsburgh — achieved a 68% AHI reduction at 12 months in patients who failed CPAP. Positional therapy reduces events in the 25-30% of patients with position-dependent apnea. Weight loss reduces AHI by approximately 30-50% in overweight patients.
Untreated OSA is independently associated with type 2 diabetes, depression, motor vehicle accidents (2-7x increased risk), and cognitive decline. A Neurology 2019 study (n=1,752) by Dr. Ricardo Osorio at NYU Langone found that severe untreated OSA accelerated cognitive decline by ten years compared to age-matched controls. If you snore, wake unrefreshed, or experience daytime sleepiness, screening is warranted.
The STOP-BANG questionnaire — developed by Dr. Frances Chung at the University of Toronto — is a validated eight-question screening tool that identifies high-risk patients with 93% sensitivity. It takes under two minutes and is freely available. Dr. Kryger recommends that primary care physicians administer STOP-BANG to every patient with hypertension, treatment-resistant depression, or type 2 diabetes, since OSA is a treatable contributing factor in all three conditions. The economic burden is substantial: untreated OSA costs the US healthcare system an estimated $149.6 billion annually in comorbidity treatment, lost productivity, and motor vehicle accidents (American Academy of Sleep Medicine, 2021 analysis).